| pubmed-article:12902833 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12902833 | lifeskim:mentions | umls-concept:C0040300 | lld:lifeskim |
| pubmed-article:12902833 | lifeskim:mentions | umls-concept:C0019080 | lld:lifeskim |
| pubmed-article:12902833 | lifeskim:mentions | umls-concept:C1512668 | lld:lifeskim |
| pubmed-article:12902833 | lifeskim:mentions | umls-concept:C0262469 | lld:lifeskim |
| pubmed-article:12902833 | lifeskim:mentions | umls-concept:C0032140 | lld:lifeskim |
| pubmed-article:12902833 | lifeskim:mentions | umls-concept:C0205234 | lld:lifeskim |
| pubmed-article:12902833 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:12902833 | pubmed:dateCreated | 2003-8-6 | lld:pubmed |
| pubmed-article:12902833 | pubmed:abstractText | Thrombolytic stroke therapy with tissue plasminogen activator (tPA) is limited by serious risks of intracerebral hemorrhage. In this study, the authors show that a novel antiactin-targeted immunoliposome significantly reduced tPA-induced hemorrhage in an established rat model of embolic focal stroke. Spontaneously hypertensive rats were subjected to focal ischemia using homologous blood clot emboli. Delayed administration of tPA (10 mg/kg, 6 hours after ischemia) induced intracerebral hemorrhage at 24 hours. In control rats treated with tPA plus vehicle, hemorrhage volumes were 9.0 +/- 2.4 uL (n = 7). In rats treated with tPA plus antiactin immunoliposomes, hemorrhage volumes were significantly reduced to 4.8 +/- 2.7 uL (n = 8, P < 0.05). No significant effects were seen when rats were treated with tPA plus a nontargeted liposome (7.8 +/- 2.1 uL, n = 9). Fluorescent immunohistochemistry showed that rhodamine-labeled targeted liposomes colocalized with vascular structures in ischemic brain that stained positive for endothelial barrier antigen, a marker of cerebral endothelial cells. These data suggest that immunoliposomes may ameliorate vascular membrane damage and reduce hemorrhagic transformation after thrombolytic therapy in cerebral ischemia. | lld:pubmed |
| pubmed-article:12902833 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12902833 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12902833 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12902833 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12902833 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12902833 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12902833 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12902833 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12902833 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12902833 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12902833 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12902833 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12902833 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:12902833 | pubmed:issn | 0271-678X | lld:pubmed |
| pubmed-article:12902833 | pubmed:author | pubmed-author:SumiiToshihis... | lld:pubmed |
| pubmed-article:12902833 | pubmed:author | pubmed-author:LoEng HEH | lld:pubmed |
| pubmed-article:12902833 | pubmed:author | pubmed-author:TorchilinVlad... | lld:pubmed |
| pubmed-article:12902833 | pubmed:author | pubmed-author:WangXiaoyingX | lld:pubmed |
| pubmed-article:12902833 | pubmed:author | pubmed-author:RammohanRamR | lld:pubmed |
| pubmed-article:12902833 | pubmed:author | pubmed-author:AsahiMinoruM | lld:pubmed |
| pubmed-article:12902833 | pubmed:author | pubmed-author:WeissigVolkma... | lld:pubmed |
| pubmed-article:12902833 | pubmed:author | pubmed-author:PauwRobert... | lld:pubmed |
| pubmed-article:12902833 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12902833 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:12902833 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12902833 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12902833 | pubmed:pagination | 895-9 | lld:pubmed |
| pubmed-article:12902833 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:meshHeading | pubmed-meshheading:12902833... | lld:pubmed |
| pubmed-article:12902833 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12902833 | pubmed:articleTitle | Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke. | lld:pubmed |
| pubmed-article:12902833 | pubmed:affiliation | Neuroprotection Research Laboratory, Department of Neurology, Massachusetts General Hospital, Program in Neuroscience, Harvard Medical School Charlestown, Charlestown, Massachusetts, U.S.A. | lld:pubmed |
| pubmed-article:12902833 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12902833 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
